Deutscher Expertenkonsens zur PD-L1-Testung („programmed cell death ligand 1") in der perioperativen Systemtherapie des muskelinvasiven Blasenkarzinoms.

Autor:	Niegisch, G., Bolenz, C., Doehn, C., Gakis, G., Hartmann, A., Müller-Huesmann, H., Reis, H., Roghmann, F., Schwamborn, K., Tiemann, K., Retz, M.
Předmět:	CYSTECTOMY CONSENSUS (Social sciences) BLADDER tumors RISK assessment MUSCLE tumors CANCER invasiveness IMMUNOCHEMISTRY PROGRAMMED death-ligand 1 IMMUNE checkpoint inhibitors COMBINED modality therapy DISEASE relapse DISEASE risk factors
Zdroj:	Die Urologie; Oct2024, Vol. 63 Issue 10, p1019-1027, 9p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink